Life sciences venture firm 4Bio Capital has secured the biopharmaceutical company as the first strategic backer for its second fund.
Kyowa Kirin, a Japan-listed specialty pharmaceutical company, has committed an undisclosed amount for the second fund to be raised by 4Bio Capital, a UK-based venture capital firm targeting advanced medical therapies.
4Bio Capital had raised more than $50m for the first close of its 4Bio Ventures II fund in September 2019 having set a $150m target for its final close. Kyowa Kirin is the first strategic pharmaceutical investor in the fund.
Kieran Mudryy, partner at 4Bio Capital, said: “We remain…
